Professor Mark Socinski joins us live from ASCO 2024 to share his views on the lung cancer data emerging from the conference.

 

In this short video update, he shares his insights on data from the LAURA and ADRIATIC trials and what they could mean for clinical practice in lung cancer management.

 

ASCO 2024 selected lung cancer abstracts

  • Osimertinib after definitive chemoradiotherapy in patients with unresectable stage 3 EGFRm NSCLC: Primary results of the phase 3 LAURA study.
    Ramalingam S, et al.
    Abstract LBA4, ASCO 2024

 

  • ADRIATIC: durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer.
    Spigel D, et al.
    Abstract LBA5, ASCO 2024

 

Prof. Mark Socinski is a Medical Oncologist and Executive Medical Director of the AdventHealth Cancer Institute, Orlando, Florida. Specialises in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. An internationally recognised expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small cell lung cancer. Research has focused on incorporating personalised medicine and molecular biomarkers in the treatment of lung cancer. Formerly Co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute and served on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance). Tenured Professor at the University of North Carolina and the University of Pittsburgh.

Prof. Mark Socinski has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, BMS, Eli Lilly, Genentech, GI Therapeutics, Guardant, Janssen, Jazz, Merck, Novartis.

Programme summary
  • clock Duration 4 MIN
  • clock Language(s) flag
Watch the video now
Other episodes in this series
ASCO 2024 lung cancer highlights

ASCO 2024 lung cancer highlights

A conference update on lung cancer clinical trial data from ASCO

Current Episode
ASCO 2024 breast cancer highlights

ASCO 2024 breast cancer highlights

How could the data impact clinical practice?

ASCO 2024 HCC highlights

ASCO 2024 HCC highlights

How could the latest clinical trial data impact the management of hepatocellular carcinoma?

ASCO 2024 upper GI cancer highlights

ASCO 2024 upper GI cancer highlights

Practice-changing upper GI trial data direct from ASCO 2024

Share this programme
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

Conference update
Oncology 
Oncogene-addicted NSCLC: Highlights from ASCO 2024

The latest non-small cell lung cancer data presented at ASCO

Experts
Prof. Nicolas Girard
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Upper lower GI cancer update ASCO 2024 Conference update
Oncology 
Upper and lower GI cancer update from ASCO 2024

GI oncologists review the latest data presented at ASCO 2024

Experts
Dr Samuel J Klempner, Dr Elizabeth Smyth, Prof. Jenny Seligmann, Dr Dominik Modest
  • clock 8 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Experts Knowledge Share Video
Oncology Hemato-oncology 
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Medical experts discuss the latest learnings from clinical practice

Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter
  • download Downloadable
    Resources
  • clock 76 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
Conference update

Episode

2

of 4

episode
Oncology 
ASCO 2024 breast cancer highlights

How could the data impact clinical practice?

Experts
Prof. Shaheenah Dawood
  • clock 3 MIN
  • calendar Jun 2024

Conference update

Episode

3

of 4

episode
Oncology 
ASCO 2024 HCC highlights

How could the latest clinical trial data impact the management of hepatocellular carcinoma?

Experts
Prof. Dr Peter R. Galle
  • clock 1 MIN
  • calendar Jun 2024

Conference update

Episode

4

of 4

episode
Oncology 
ASCO 2024 upper GI cancer highlights

Practice-changing upper GI trial data direct from ASCO 2024

Experts
Dr Samuel J Klempner, Dr Elizabeth Smyth
  • clock 3 MIN
  • calendar Jun 2024

This educational programme is supported by an Independent Medical Education Grant from Bayer.